Home » Stocks » Strongbridge Biopharma

Strongbridge Biopharma PLC (SBBP)

Stock Price: $3.99 USD 0.01 (0.25%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 216.88M
Revenue (ttm) 25.72M
Net Income (ttm) -52.74M
Shares Out 54.36M
EPS (ttm) -1.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 12, 2020
Last Price $3.99
Previous Close $3.98
Change ($) 0.01
Change (%) 0.25%
Day's Open 3.99
Day's Range 3.75 - 4.16
Day's Volume 1,092,229
52-Week Range 1.43 - 4.63

More Stats

Market Cap 216.88M
Enterprise Value 163.97M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 54.36M
Float 26.92M
EPS (basic) -0.96
EPS (diluted) -1.05
FCF / Share -0.66
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 684,042
Short Ratio 1.51
Short % of Float 1.27%
Beta 4.69
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.43
PB Ratio 4.53
Revenue 25.72M
Operating Income -56.75M
Net Income -52.74M
Free Cash Flow -35.79M
Net Cash 52.91M
Net Cash / Share 0.97
Gross Margin 69.55%
Operating Margin -220.61%
Profit Margin -205.00%
FCF Margin -139.13%
ROA -28.42%
ROE -75.80%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 6
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(108.77% upside)
Current: $3.99
Target: 8.33
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth20.44%155.85%-----
Gross Profit17.8914.045.56----
Operating Income-67.09-81.92-73.74-50.73-42.85-10.43-5.19
Net Income-49.4531.85-113-48.60-43.58-9.67-5.30
Shares Outstanding54.1846.3036.5421.5516.618.046.02
Earnings Per Share-0.910.69-3.11-2.27-2.62-1.20-0.88
Operating Cash Flow-44.78-84.58-45.34-31.71-37.36-9.50-3.48
Capital Expenditures-0.07-0.33---0.03-0.02-
Free Cash Flow-44.86-84.90-45.34-31.71-37.39-9.53-3.48
Cash & Equivalents78.1012257.5166.8451.6215.6314.90
Total Debt--37.7918.43---
Net Cash / Debt78.1012219.7248.4051.6215.6314.90
Book Value72.19113-11.9166.9790.3618.8217.80
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Strongbridge Biopharma PLC
Country United States
Employees 71
CEO John H. Johnson

Stock Information

Ticker Symbol SBBP
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SBBP
IPO Date October 16, 2015


Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.